Mebendazole


Full Prescribing Info
Dosage/Direction for Use

Oral
Trichuriasis
Adult: 100 mg bid for 3 consecutive days or 500 mg as single dose.
Child: >2 years
Same as adult dose.

Oral
Ascariasis
Adult: 100 mg bid for 3 consecutive days or 500 mg as single dose.
Child: >2 years
Same as adult dose.

Oral
Hookworm infections
Adult: 100 mg bid for 3 consecutive days or 500 mg as single dose.
Child: >2 years
Same as adult dose.

Oral
Enterobiasis
Adult: 100 mg as single dose; may repeat if necessary 2-3 weeks after initial treatment.
Child: >2 years
Same as adult dose.
Administration
May be taken with or without food.
Contraindications
Hypersensitivity. Pregnancy.
Special Precautions
Prolonged use. Hepatic impairment. Lactation. Children < 2 years. Monitoring Parameters Monitor blood count on higher doses and prolonged duration. Periodic assessment of haematologic, hepatic and renal function. Check for helminth ova in faeces within 3-4 weeks following initial therapy.
Adverse Reactions
Significant: Bone marrow suppression e.g. agranulocytosis, neutropenia. Gastrointestinal disorders: Diarrhoea, flatulence, abdominal pain, anorexia, nausea, vomiting. Hepatobiliary disorders: Hepatitis, abnormal liver tests. Nervous system disorder: Convulsion, headache, dizziness. Skin and subcutaneous tissue disorders: Exanthema, angioedema, urticaria, alopecia, rash.
Potentially Fatal: Toxic epidermal necrolysis, Stevens-Johnson syndrome.
Overdosage
Symptoms: Abdominal cramps, nausea, vomiting, diarrhoea; rarely, alopecia, reversible liver function abnormalities, hepatitis, agranulocytosis, neutropenia, glomerulonephritis. Management: Administration of activated charcoal may be given.
Drug Interactions
Increased plasma concentration with cimetidine. Decreased serum concentration with carbamazepine, fosphenytoin, phenytoin.
Potentially Fatal: Co-administration of metronidazole may increase risk of Stevens-Johnson syndrome/toxic epidermal necrolysis.
Food Interaction
Increased serum levels with food.
Action
Mebendazole, a benzimidazole carbamate derivative, is an anthelmintic with activity against most nematodes and some other worms by interfering the formation of helminth microtubules and causes ultrastructural degenerative changes in the intestine. It selectively and irreversibly blocks glucose uptake and disrupts digestive and reproductive functions resulting to immobilization, inhibition of egg production and death of the helminth.
Absorption: Poorly absorbed from the GI tract. Increased serum level with food. Time to peak plasma concentration: 1.5-7.25 hours.
Distribution: Crosses blood-brain barrier and enters breast milk. Volume of distribution: 1-2 L/kg. Plasma protein binding: 90-95%
Metabolism: Extensively metabolised in the liver via first pass effect. Primary metabolite: 2-amine hydrolysed metabolite.
Excretion: Mainly via faeces; urine (<2%). Elimination half-life: 3-6 hours.
Storage
Oral: Store between 20-25°C. Protect from light.
CIMS Class
ATC Classification
P02CA01 - mebendazole ; Belongs to the class of benzimidazole derivative agents. Used as antinematodal.
Disclaimer: This information is independently developed by CIMS based on mebendazole from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in